{Bis[2-(diphenyl­phosphino)eth­yl]phenyl­phosphine-κ3 P,P′,P′′}chloridoplatinium(II) hexa­fluoridophosphate

In the title compound, [PtCl(C34H33P3)]PF6, the PtII cation adopts a distorted square-planar PtClP3 geometry, arising from the P,P′,P′′-tridentate triphos ligand and a chloride ion. Four of the F atoms of the PF6 − anion are disordered over two sets of positions in a 0.614 (17):0.386 (17) ratio

[Diphenyldi(pyrazol-1-yl)methane]­dinitratocobalt(II)

In the title compound, [Co(NO3)2(C19H16N4)], the diphenyl­dipyrazolylmethane ligand coordinates to CoII in a bidentate fashion forming a six-membered ring with an approximate boat configuration. The mean planes of the two pyrazolyl rings are separated by an angle of 39.6 (2)°. The coordination at the CoII center is best described as distorted octa­hedral with two NO3 − anions serving as bidentate ligands for charge balance. The dihedral angle between the mean planes of the two nitrate rings is 85.0 (1)° and that between the mean planes of the two phenyl rings is 73.7 (1)°. The crystal structure is stabilized by weak inter­molecular C—H⋯O and intra­molecular C—H⋯N hydrogen-bond inter­actions

2-(Thio­phen-2-yl)-1-(thio­phen-2-ylmeth­yl)-1H-benzimidazole

In the title compound, C16H12N2S2, the thio­phene groups are rotationally disordered over two sets of sites, by approximately 180°, with occupancy ratios of 0.916 (2):0.084 (2) and 0.903 (2):0.097 (2). The major components of the thio­phene and methyl­ene substituted thio­phene rings are canted by 24.06 (12) and 85.07 (10)°, respectively, from the benzimidazole ring system plane and the dihedral angle between the major component thio­phene ring planes is 84.90 (14)°. In the crystal, there is a weak C—H⋯N hydrogen bond which links mol­ecules into chains

Bis(1,4,7-trithia­cyclo­nona­ne)nickel(II) bis­(tetra­fluorido­borate) nitro­methane disolvate

The homoleptic thio­ether title complex, [Ni(C6H12S3)2](BF4)2·2CH3NO2, shows the expeced hexa­kis­(thio­ether) octa­hedral environment around the NiII atom. It crystallized as two crystallographically independent complex cations, [Ni(9S3)2]2+ (9S3 = 1,4,7-trithia­cyclo­nona­ne), within the unit cell where each NiII lies on an inversion center. In addition to the complex cations, there are two crystallographically independent BF4 − anions present to balance the charge, and each shows disorder along a pseudo-C 3 axis with ratios of 0.53 (2):0.47 (2) and 0.55 (2):0.45 (2). Two nitro­methane solvent mol­ecules per complex cation are also present in the unit cell

Emotion expression modulates perception of animacy from faces

Discriminating real human faces from artificial can be achieved quickly and accurately by face-processing networks, but less is known about what stimulus qualities or interindividual differences in the perceiver might influence whether a face is perceived as being alive. In the present studies, morphed stimuli differing in levels of animacy were created. Participants made judgements about whether the face appeared animate at different levels along the morph continuum. The faces varied in terms of emotional expression (happy vs. neutral) and gender. Male faces were judged to be animate at a lower threshold (i.e., closer to the inanimate end of the continuum) than female faces. Animacy was also perceived more readily in faces with happy expressions than neutral. These effects were observed across two separate studies involving different participants and different sets of stimuli (animate faces morphed with dolls or those morphed with computer generated faces). Finally, the influence of interindividual variability in personality traits on animacy perception was examined. This revealed that an externally oriented cognitive style, a component of alexithymia, was associated with lower thresholds for perceiving animacy, for animate faces morphed with dolls. The findings are discussed in relation to inter- and intra-individual variability in animacy perception and social interaction

Structure-Based Vaccines Provide Protection in a Mouse Model of Ehrlichiosis

infection. were protected against the pathogen.Our results demonstrate the power of structural vaccines and could be a new strategy in the development of vaccines to provide protection against pathogenic microorganisms

EGG: hatching a mock Universe from empirical prescriptions⋆

This paper introduces EGG, the Empirical Galaxy Generator, a tool designed within the ASTRODEEP collaboration to generate mock galaxy catalogs for deep fields with realistic fluxes and simple morphologies. The simulation procedure is based exclusively on empirical prescriptions -- rather than first principles -- to provide the most accurate match with observations at 0<z<7. In particular, we consider that galaxies can be either quiescent or star-forming, and use their stellar mass (M*) and redshift (z) as the fundamental properties from which all the other observables can be statistically derived. Drawing z and M* from the observed galaxy stellar mass functions, we associate a star formation rate (SFR) to each galaxy from the tight SFR-M* main sequence, while dust attenuation, optical colors and morphologies (including bulge-to-total ratios, sizes and aspect ratios) are obtained from empirical relations that we establish from the high quality Hubble and Herschel observations available in the CANDELS fields. Random scatter is introduced in each step to reproduce the observed distributions of each parameter. Based on these observables, a panchromatic spectral energy distribution (SED) is selected for each galaxy and synthetic photometry is produced by integrating the redshifted SED in common broad-band filters. Finally, the mock galaxies are placed on the sky at random positions with a fixed angular two-point correlation function to implement basic clustering. The resulting flux catalogs reproduce accurately the observed number counts in all broad bands from the ultraviolet up to the sub-millimeter, and can be directly fed to image simulators such as Skymaker. The images can then be used to test source extraction softwares and image-based techniques such as stacking. EGG is open-source, and is made available to the community together with a set of pre-generated catalogs and images.Comment: 24 pages, 18 figures, accepted for publication in A&

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure &lt; 100 mmHg (n = 1127), estimated glomerular filtration rate &lt; 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation